Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi

被引:47
作者
Sumimoto, H
Hirata, K
Yamagata, S
Miyoshi, H
Miyagishi, M
Taira, K
Kawakami, Y
机构
[1] Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, Tokyo 1608582, Japan
[2] RIKEN, Tsukuba Inst, Subteam Manipulat Cell Fate, Tsukuba, Ibaraki, Japan
[3] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo, Japan
关键词
p27(Kip1); BRAF; Skp-2; RNA interference; lentivirus;
D O I
10.1002/ijc.21286
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
p27(Kip1) that regulates the G1/S transition of cell cycle and inhibits Rho A signaling is frequently lost in several cancers leading to the deregulation of cell growth and cell motility. Mitogen-activated protein kinases (MAPK) regulate the export of p27(Kip1) from nucleus to cytoplasm, followed by the degradation with proteases. Skp-2, a subunit of an SCF ubiquitin-protein ligase complex responsible for the ubiquitination of P27(Kip1), is upregulated frequently in several cancers, leading to the decrease of p27(Kip1). We applied human immunodeficiency virus (HIV) lentivirus-mediated RNA interference (RNAi) to melanoma cells with the BRAF mutation (V599E) and overexpressed Skp-2 and found that the simultaneous suppression of these activated oncogenes resulted in the effective inhibition of in vitro cell growth and invasive ability of melanoma cells accompanied by the additional increase of P27(Kip1). Our results suggest that gene therapy against melanoma with the enhanced MAPK and ubiquitin-proteasomal pathways could be a specific and effective therapeutic strategy for cancers. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:472 / 476
页数:5
相关论文
共 16 条
[1]   p27Kip1 modulates cell migration through the regulation of RhoA activation [J].
Besson, A ;
Gurian-West, M ;
Schmidt, A ;
Hall, A ;
Roberts, JM .
GENES & DEVELOPMENT, 2004, 18 (08) :862-876
[2]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[3]   MAP kinase-dependent degradation of p27Kip1 by calpains in choroidal melanoma cells -: Requirement of p27Kip1 nuclear export [J].
Delmas, C ;
Aragou, N ;
Poussard, S ;
Cottin, P ;
Darbon, JM ;
Manenti, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (14) :12443-12451
[4]   The murine gene p27Kip1 is haplo-insufficient for tumour suppression [J].
Fero, ML ;
Randel, E ;
Gurley, KE ;
Roberts, JM ;
Kemp, CJ .
NATURE, 1998, 396 (6707) :177-180
[5]   Skp2 is oncogenic and overexpressed in human cancers [J].
Gstaiger, M ;
Jordan, R ;
Lim, M ;
Catzavelos, C ;
Mestan, J ;
Slingerland, J ;
Krek, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (09) :5043-5048
[6]  
Hingorani SR, 2003, CANCER RES, V63, P5198
[7]  
Kimura ET, 2003, CANCER RES, V63, P1454
[8]   Role of the F-box protein Skp2 in lymphomagenesis [J].
Latres, E ;
Chiarle, R ;
Schulman, BA ;
Pavletich, NP ;
Pellicer, A ;
Inghirami, C ;
Pagano, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) :2515-2520
[9]  
Masuda T, 2002, CANCER RES, V62, P3819
[10]   A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? [J].
Smalley, KSM .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (05) :527-532